Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Key facts
- Who runs it
- Todd C. Lee MD MPH FIDSA
- Where
- Canada8 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 20 May 2024
- Expected to end
- Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ertapenem
- Placebo
- Record updated
- 2 November 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Adult >=18 years old
- S. aureus bacteremia within the past 48 hours:; with any unknown MRSA status (in centers with <15% prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR; which has already been shown to be MSSA
- Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug); NOTE: Up to an additional 12-24 hours of open label non-study VANCOMYCIN, LINEZOLID or DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been excluded
Who cannot take part
- Previously enrolled
- Patients whose isolate is identified as MRSA post-enrollment will be subsequently excluded (see below); Note that because MSSA is much more common than MRSA in Canada (90% of all S. aureus bacteremia at MUHC, for example, are MSSA and in the presence of a negative MRSA screening swab or unknown MRSA status, this means that the risk of MRSA is less than 5%). We believe time to combination therapy is likely linked to benefit, therefore we will recruit the patients as soon as S. aureus is identified but potentially prior to confirmation the organism is MSSA. Where possible, rapid MRSA detection techniques will be deployed; however with conventional screening this will mean approximately a 12-24 hours delay. Organisms subsequently identified as MRSA will be excluded from the intention to treat analysis and the sample size will be adjusted accordingly to ensure the total enrollment meets study goals
- Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)
- Known seizure disorder
- Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of severe illness); Administrative:
- Clinical:
- At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at >24 hours incubation
- Any receipt of valproic acid
- Expected mortality within 48 hours
- Need for critical care resources but "do not resuscitate" status precludes the receipt of critical care
- Refusal to provide informed consent
- Refusal of healthcare team to participate
- No reliable means of outpatient contact (telephone/email/text)
Other criteria
- The participant must fulfil all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria to be eligible for this sub-study:
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed.
Read full original descriptionShow less
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
The 2 groups in the trial
- ErtapenemTreatment being tested
Ertapenem 1g IV daily infused over 2 hours x 5 days
- PlaceboPlacebo, for comparison
Saline placebo infused daily over 2 hours x 5 days
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
- Criteria questions
- Built from NCT04886284, who can take part
- Publications
- Incidence and factors associated with rapid blood culture sterilization among patients receiving ertapenem combination therapy for MSSA bacteremia.Antimicrobial agents and chemotherapy, 2026
- Record updated
- 2 November 2026